Vivanza Biosciences appoints CS Vishal Sureshbhai Katarmal
Vivanza Biosciences Limited appointed CS Vishal Sureshbhai Katarmal as Company Secretary and Compliance Officer effective July 9, 2026. The Board approved the appointment during a meeting held on the same day, pursuant to Section 203 of the Companies Act, 2013, and Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

*this image is generated using AI for illustrative purposes only.
Vivanza Biosciences Limited appointed CS Vishal Sureshbhai Katarmal as its Company Secretary and Compliance Officer effective July 9, 2026, to strengthen its regulatory compliance framework. The Board of Directors approved the appointment during a meeting held on July 9, 2026, pursuant to Section 203 of the Companies Act, 2013, and Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Appointment Details
CS Vishal Sureshbhai Katarmal is an Associate Member of the Institute of Company Secretaries of India (ACS: 78544). He brings experience in dealing with matters of the Companies Act, Listing Regulations, and allied laws. The appointment follows the requirements of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
| Particulars | Details |
|---|---|
| Appointee Name | CS Vishal Sureshbhai Katarmal |
| Designation | Company Secretary and Compliance Officer |
| Membership Number | ACS: 78544 |
| Effective Date | July 9, 2026 |
Board Meeting Proceedings
The meeting of the Board of Directors commenced at 15:15 P.M. and concluded at 15:30 P.M. The disclosure was submitted to the stock exchange in compliance with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015.
Historical Stock Returns for Vivanza Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -2.63% | +8.82% | -17.41% | -12.32% | -84.95% |
What specific regulatory challenges is Vivanza Biosciences currently facing that prompted the strengthening of its compliance framework?
How will CS Katarmal's previous experience influence Vivanza Biosciences' approach to upcoming SEBI regulatory changes?
Are there additional senior management appointments planned to support the company's governance structure?































